This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RENB Lunai Bioworks (RENB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Lunai Bioworks Stock (NASDAQ:RENB) Get Lunai Bioworks alerts:Sign Up Key Stats Today's Range$1.13▼$1.4350-Day Range$1.30▼$2.3852-Week Range$0.12▼$1.43Volume880,400 shsAverage Volume2.93 million shsMarket Capitalization$250.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. Read More Receive RENB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lunai Bioworks and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RENB Stock News HeadlinesLunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours SessionJune 16, 2026 | benzinga.comLunai Bioworks Furloughs Staff Amid Liquidity ConstraintsMarch 5, 2026 | tipranks.comFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are preparing to launch Project Janus, a high-priority initiative centered on a new fuel technology. One obscure defense contractor holds a five-year head start on every competitor, with the first powerplant expected to go live before December 18, 2026. The full story, including the company name and ticker symbol, is available now.August 22 at 1:00 AM | Banyan Hill Publishing (Ad)Lunai Bioworks Faces Nasdaq Delisting, Hearing ScheduledFebruary 23, 2026 | tipranks.comLunai Bioworks Secures $3.1M in Private PlacementNovember 25, 2025 | tipranks.comLunai Bioworks announces early results from AI-based platformOctober 31, 2025 | msn.comLunai Bioworks unveils new corporate identitySeptember 30, 2025 | msn.comLunai Bioworks advances biomarker discovery preclinical program in Parkinson’sSeptember 25, 2025 | msn.comSee More Headlines RENB Stock Analysis - Frequently Asked Questions How were Lunai Bioworks' earnings last quarter? Lunai Bioworks Inc. (NASDAQ:RENB) posted its quarterly earnings data on Wednesday, February, 19th. The company reported ($0.20) earnings per share for the quarter. When did Lunai Bioworks' stock split? Shares of Lunai Bioworks reverse split on Monday, September 29th 2025.The 1-10 reverse split was announced on Wednesday, September 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Lunai Bioworks IPO? Lunai Bioworks (RENB) raised $12 million in an initial public offering (IPO) on the week of December 10th 2018. The company issued 2,400,000 shares at $5.00 per share. What other stocks do shareholders of Lunai Bioworks own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lunai Bioworks investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW). Company Calendar Last Earnings2/19/2025Today8/22/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RENB CIK1527728 Webwww.enochianbio.com Phone305-918-1980FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-60.38% Return on Assets-47.04% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book1.73Miscellaneous Outstanding Shares162,390,000Free Float171,258,000Market Cap$250.24 million OptionableOptionable Beta0.54 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:RENB) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are preparing to launch Project Janus, a high-priority initiative cente...Banyan Hill Publishing | SponsoredBuy THIS potential Musk supplier before WednesdayA little-known company trading under $1 could become Elon Musk's next supplier, with a possible announcement e...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lunai Bioworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lunai Bioworks With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RENB Stock Alerts